ReviewPharmaceutics2018
A Comprehensive Map of FDA-Approved Pharmaceutical Products.
Review in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed.
- 3D-Printable and Bioelectronic-Compatible Graphene-Reinforced PLA Nanocomposites Rejuvenate Aged Bone Regeneration Through Glycolytic Reprogramming.Advanced healthcare materials · 2026Article
- Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access.Clinical pharmacology and therapeutics · 2026Article
- Redefining long-acting injectables: the emerging role of extracellular vesicles in sustained drug delivery.Drug delivery and translational research · 2026Review
- Hype vs. Health: How Approved Nanomedicines Have Met (or Missed) Early Predictions.Nanomaterials (Basel, Switzerland) · 2026Article
- Nanomedicine-Based Strategies for Multiple Myeloma Therapy.International journal of nanomedicine · 2026Review
- Soluplus Stabilized Amorphous Dispersions for Enhanced Oral Absorption of Felodipine.Current drug delivery · 2026Article
- Self-reinforcing nanomedicine orchestrates EPR effect and neutrophil hitchhiking for spatiotemporal accumulation in solid tumors.Journal of nanobiotechnology · 2025Article
- Delivery of nucleic acid drugs for tumor therapy: Opportunities and challenges.Fundamental research · 2025Review
- cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy.Circulation research · 2025Article
- Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Developments in nanotechnology approaches for the treatment of solid tumors.Experimental hematology & oncology · 2025Review
- Nucleic acid therapeutics: Past, present, and future.Molecular therapy. Nucleic acids · 2025Review
- Enhanced Photosensitivity and Surfactant Resistance in Nanopolymersome Membranes as a Function of Gold Nanoparticle Incorporation.ACS applied optical materials · 2025Article
- Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems.Pharmaceutics · 2025Review
- Establishing a Pharmacoinformatics Repository of Approved Medicines: A Database to Support Drug Product Development.Molecular pharmaceutics · 2025Article
- Quercetin-Loaded Nanoparticle-Modified Decellularized Tissue-Engineered Vascular Graft Regulates Macrophage Polarization and Promotes In Vivo Graft Remodeling.International journal of nanomedicine · 2025Article
- Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.International journal of nanomedicine · 2025Article
- Data-driven development of an oral lipid-based nanoparticle formulation of a hydrophobic drug.Drug delivery and translational research · 2024Article
- Impact of Drug-Mediated Inhibition of Intestinal Transporters on Nutrient and Endogenous Substrate Disposition…an Afterthought?Pharmaceutics · 2024Review
- State of the Art of Silica Nanoparticles: An Overview on Biodistribution and Preclinical Toxicity Studies.The AAPS journal · 2024Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing research and development (R&D) difficulty of new molecular entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention. This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the technical barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems. According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technology barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly technical barriers had less competition and greater market potential. Our study provides a comprehensive insight into FDA-approved products and deep analysis of the technical barriers for advanced drug delivery systems. In the future, the R&D of new molecular entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.